» Articles » PMID: 16455980

Mast Cells Enhance T Cell Activation: Importance of Mast Cell Costimulatory Molecules and Secreted TNF

Overview
Journal J Immunol
Date 2006 Feb 4
PMID 16455980
Citations 166
Authors
Affiliations
Soon will be listed here.
Abstract

We recently reported that mast cells stimulated via FcepsilonRI aggregation can enhance T cell activation by a TNF-dependent mechanism. However, the molecular mechanisms responsible for such IgE-, Ag- (Ag-), and mast cell-dependent enhancement of T cell activation remain unknown. In this study we showed that mouse bone marrow-derived cultured mast cells express various costimulatory molecules, including members of the B7 family (ICOS ligand (ICOSL), PD-L1, and PD-L2) and the TNF/TNFR families (OX40 ligand (OX40L), CD153, Fas, 4-1BB, and glucocorticoid-induced TNFR). ICOSL, PD-L1, PD-L2, and OX40L also are expressed on APCs such as dendritic cells and can modulate T cell function. We found that IgE- and Ag-dependent mast cell enhancement of T cell activation required secreted TNF; that TNF can increase the surface expression of OX40, ICOS, PD-1, and other costimulatory molecules on CD3(+) T cells; and that a neutralizing Ab to OX40L, but not neutralizing Abs to ICOSL or PD-L1, significantly reduced IgE/Ag-dependent mast cell-mediated enhancement of T cell activation. These results indicate that the secretion of soluble TNF and direct cell-cell interactions between mast cell OX40L and T cell OX40 contribute to the ability of IgE- and Ag-stimulated mouse mast cells to enhance T cell activation.

Citing Articles

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.


IL-33-primed human mast cells drive IL-9 production by CD4 effector T cells in an OX40L-dependent manner.

Battut L, Leveque E, Valitutti S, Cenac N, Dietrich G, Espinosa E Front Immunol. 2024; 15:1470546.

PMID: 39416773 PMC: 11479898. DOI: 10.3389/fimmu.2024.1470546.


Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy.

Li C, Yu X, Han X, Lian C, Wang Z, Shao S iScience. 2024; 27(9):110750.

PMID: 39280627 PMC: 11399700. DOI: 10.1016/j.isci.2024.110750.


The innate face of Giant Cell Arteritis: Insight into cellular and molecular innate immunity pathways to unravel new possible biomarkers of disease.

Rizzo C, Barbera L, Miceli G, Tuttolomondo A, Guggino G Front Mol Med. 2024; 2:933161.

PMID: 39086970 PMC: 11285707. DOI: 10.3389/fmmed.2022.933161.


A Multi-Omics Analysis of an Exhausted T Cells' Molecular Signature in Pan-Cancer.

Rigopoulos C, Georgakopoulos-Soares I, Zaravinos A J Pers Med. 2024; 14(7).

PMID: 39064019 PMC: 11278172. DOI: 10.3390/jpm14070765.